BD (Becton, Dickinson and Company), a medical technology company, has announced that its Liverty TIPS Stent Graft has received CE Mark approval, enabling its use across the European Union for the treatment of complications arising from portal hypertension. The device is designed to support patients with cirrhosis, a chronic liver condition that can lead to serious and potentially life-threatening complications.

Portal hypertension, a common consequence of cirrhosis, occurs when increased pressure in the portal vein restricts blood flow through the liver. This can result in complications such as variceal bleeding and fluid accumulation in the abdomen or chest. Transjugular intrahepatic portosystemic shunt (TIPS) procedures are widely used to relieve these symptoms by lowering portal pressure and improving circulation.

The Liverty TIPS Stent Graft has been developed to offer greater flexibility and personalised treatment options for patients undergoing TIPS procedures. It features an adjustable inner diameter ranging from 6 mm to 10 mm, allowing physicians to tailor the device according to a patient’s specific clinical needs. It also offers the broadest range of covered stent lengths currently available for TIPS applications.

The device incorporates a self-expanding nitinol frame and a dual-layer ePTFE encapsulation with carbon-impregnated inner lining, designed to improve durability and performance. It is delivered using a fully constrained triaxial delivery system intended to enhance placement accuracy, control and ease of use during procedures.

BD said the CE Mark represents a significant advancement in portal hypertension care by improving physicians’ ability to customise therapy and potentially enhance long-term patient outcomes.

The company also announced that data from the pivotal ARCH clinical trial evaluating the safety and effectiveness of the Liverty TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology (SIR) Annual Scientific Meeting on April 12, 2026. The global prospective, multi-centre study is designed to assess the device’s performance in patients with complications related to portal hypertension.

Clinical experts involved in the study noted that the Liverty TIPS Stent Graft could represent an important improvement in managing complex liver disease. Its adjustable diameter and advanced delivery system are expected to help physicians better match shunt size to individual patient physiology, a critical factor in achieving safe and effective outcomes.

While the device is now approved for use in Europe, BD clarified that in the United States the Liverty TIPS Stent Graft remains investigational and is currently limited to research use only.

With this launch, BD aims to strengthen its portfolio of interventional therapies and support better outcomes for patients living with chronic liver disease and portal hypertension.